Brokerages Set Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Target Price at $32.00

Odyssey Therapeutics, Inc. (NASDAQ:ODTX) has been assigned an average recommendation of “Moderate Buy” from the six brokerages that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $32.00.

A number of analysts have recently weighed in on the company. Wall Street Zen raised Odyssey Therapeutics to a “hold” rating in a research report on Saturday, May 16th. Wedbush assumed coverage on Odyssey Therapeutics in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $30.00 price objective on the stock. Oppenheimer assumed coverage on Odyssey Therapeutics in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $40.00 price objective on the stock. JPMorgan Chase & Co. assumed coverage on Odyssey Therapeutics in a research report on Tuesday, June 2nd. They set an “overweight” rating and a $26.00 price objective on the stock. Finally, Cantor Fitzgerald assumed coverage on shares of Odyssey Therapeutics in a research note on Tuesday, June 2nd. They set an “overweight” rating for the company.

Odyssey Therapeutics Price Performance

Odyssey Therapeutics stock opened at $17.12 on Tuesday. Odyssey Therapeutics has a twelve month low of $15.35 and a twelve month high of $20.30.

Insider Activity

In other news, Director Dimension Capital Ii, L.P. bought 1,111,111 shares of the stock in a transaction that occurred on Friday, May 8th. The stock was purchased at an average price of $18.00 per share, for a total transaction of $19,999,998.00. Following the completion of the purchase, the director owned 3,333,516 shares in the company, valued at approximately $60,003,288. This trade represents a 50.00% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Shelley Chu bought 11,111 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were purchased at an average price of $18.00 per share, with a total value of $199,998.00. Following the purchase, the director owned 11,111 shares of the company’s stock, valued at approximately $199,998. This represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. In the last quarter, insiders have acquired 4,183,777 shares of company stock valued at $75,319,986.